The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain

Experimental Neurology

Volumn 249, Issue , 2013, Pages 144-148

  Mazarei, G ^a   Budac, D P ^c   Lu, G ^a   Lee, H ^a   Moller T ^c   Leavitt, B R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

3 Hydroxykynurenine; Huntingtin; Huntington disease; Indoleamine 2,3 dioxygenase; Kynurenine pathway; NMDA receptor mediated excitotoxicity; Striatum

Indexed keywords

3 HYDROXYKYNURENINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; EXCITOTOXICITY; FEMALE; GENE EXPRESSION; HUNTINGTON CHOREA; IDO1 GENE; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

3-HYDROXYKYNURENINE; BBB; BLOOD BRAIN BARRIER; HD; HUNTINGTIN; HUNTINGTON DISEASE; HUNTINGTON'S DISEASE; IDO1; IDO2; INDOLEAMINE 2,3-DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE (GENE); INDOLEAMINE 2,3-DIOXYGENASE 2 (GENE); KA; KP; KYN; KYNURENIC ACID; KYNURENINE; KYNURENINE PATHWAY; LC-MS/MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MEDIUM SPINY NEURONS; MSN; N-METHYL-D-ASPARTATE; NMDA; NMDA RECEPTOR-MEDIATED EXCITOTOXICITY; QA; QUINOLINIC ACID; SEROTONIN PATHWAY; SP; STRIATUM; TDO2; TRP; TRYPTOPHAN; TRYPTOPHAN 2,3-DIOXYGENASE (GENE);

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUNTINGTON DISEASE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84884542405     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.08.007     Document Type: Article

References (45)

1. Amori L., Guidetti P., Pellicciari R., Kajii Y., Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 2009, 109:316-325.
2. Baban B., Chandler P., McCool D., Marshall B., Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 2004, 61:67-77.
3. Baran H., Hainfellner J.A., Kepplinger B., Mazal P.R., Schmid H., Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J. Neural Transm. 2000, 107:1127-1138.
4. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
5. Bonda D.J., Mailankot M., Stone J.G., Garrett M.R., Staniszewska M., Castellani R.J., Siedlak S.L., Zhu X., Lee H.-G., Perry G., Nagaraj R.H., Smith M.A. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010, 15:161-168.
6. Campesan S., Green E.W., Breda C., Sathyasaikumar K.V., Muchowski P.J., Schwarcz R., Kyriacou C.P., Giorgini F. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 2011, 21(11):961-966. (Jun 7).
7. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernández J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
8. Chen Y., Stankovic R., Cullen K.M., Meininger V., Garner B., Coggan S., Grant R., Brew B.J., Guillemin G.J. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 2010, 18:132-142.
9. Clark C.J., Mackay G.M., Smythe G.A., Bustamante S., Stone T.W., Phillips R.S. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun. 2005, 73:5249-5251.
10. Darlington L.G., Mackay G.M., Forrest C.M., Stoy N., George C., Stone T.W. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur. J. Neurosci. 2007, 26:2211-2221.
11. Fu X., Lawson M.A., Kelley K.W., Dantzer R. HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J. Neuroinflammation 2011, 8:88.
12. Gál E.M., Sherman A.D. l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 1980, 5:223-239.
13. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
14. Guidetti P., Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 1999, 11:3857-3863.
15. Guidetti P., Luthi-Carter R.E., Augood S.J., Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 2004, 17:455-461.
16. Guidetti P., Bates G.P., Graham R.K., Hayden M.R., Leavitt B.R., MacDonald M.E., Slow E.J., Wheeler V.C., Woodman B., Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 2006, 23:190-197.
17. Guillemin G.J., Brew B.J., Noonan C.E., Takikawa O., Cullen K.M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol. 2005, 31:395-404.
18. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
19. Guillemin G.J., Cullen K.M., Lim C.K., Smythe G.A., Garner B., Kapoor V., Takikawa O., Brew B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 2007, 27:12884-12892.
20. Higuchi K., Hayaishi O. Enzymic formation of d-kynurenine from d-tryptophan. Arch. Biochem. Biophys. 1967, 120:397-403.
21. Hou D.-Y., Muller A.J., Sharma M.D., DuHadaway J., Banerjee T., Johnson M., Mellor A.L., Prendergast G.C., Munn D.H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007, 67:792-801.
22. Huengsberg M., Winer J.B., Gompels M., Round R., Ross J., Shahmanesh M. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin. Chem. 1998, 44:858-862.
23. Jung I.D., Lee M.-G., Chang J.H., Lee J.S., Jeong Y.-I., Lee C.-M., Park W.S., Han J., Seo S.-K., Lee S.Y., Park Y.-M. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J. Immunol. 2009, 182:3146-3154.
24. Kanai M., Funakoshi H., Takahashi H., Hayakawa T., Mizuno S., Matsumoto K., Nakamura T. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain 2009, 2:8.
25. Kiank C., Zeden J.-P., Drude S., Domanska G., Fusch G., Otten W., Schuett C. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 2010, 5:e11825.
26. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122(8):2940-2954. (Aug 1).
27. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
28. Mazarei G., Neal S.J., Becanovic K., Luthi-Carter R., Simpson E.M., Leavitt B.R. Expression analysis of novel striatal-enriched genes in Huntington disease. Hum. Mol. Genet. 2010, 19:609-622.
29. Mazarei G., Budac D.P., Lu G., Adomat H., Tomlinson Guns E.S., Möller T., Leavitt B.R. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J. Neurochem. 2013, http://dx.doi.org/10.1111/jnc.12350 (Jun 21, Electronic publication ahead of print).
30. O'Connor J.C., Lawson M.A., André C., Briley E.M., Szegedi S.S., Lestage J., Castanon N., Herkenham M., Dantzer R., Kelley K.W. Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212.
31. Okamoto S.-I., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.-S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
32. Ravishankar B., Liu H., Shinde R., Chandler P., Baban B., Tanaka M., Munn D.H., Mellor A.L., Karlsson M.C.I., McGaha T.L. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3909-3914.
33. Sapko M.T., Guidetti P., Yu P., Tagle D.A., Pellicciari R., Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp. Neurol. 2006, 197:31-40.
34. Sardar A.M., Bell J.E., Reynolds G.P. Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J. Neurochem. 1995, 64:932-935.
35. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
36. Szabó N., Kincses Z.T., Toldi J., Vécsei L. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach. J. Neurol. Sci. 2011, 310(1-2):256-260. (Nov 15).
37. Szalardy L., Klivenyi P., Zadori D., Fulop F., Toldi J., Vecsei L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr. Med. Chem. 2012, 19(13):1899-1920.
38. van der Goot A.T., Zhu W., Vázquez-Manrique R.P., Seinstra R.I., Dettmer K., Michels H., Farina F., Krijnen J., Melki R., Buijsman R.C., Ruiz Silva M., Thijssen K.L., Kema I.P., Neri C., Oefner P.J., Nollen E.A.A. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:14912-14917.
39. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. (RESEARCH0034).
40. Vécsei L., Szalárdy L., Fülöp F., Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12(1):64-82. (Jan).
41. Walker D.G., Link J., Lue L.-F., Dalsing-Hernandez J.E., Boyes B.E. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J. Leukoc. Biol. 2006, 79:596-610.
42. Widner B., Leblhuber F., Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J. Neural Transm. 2002, 109:181-189.
43. Yamada A., Akimoto H., Kagawa S., Guillemin G.J., Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J. Neurochem. 2009, 110:791-800.
44. Yuasa H.J., Ball H.J., Ho Y.F., Austin C.J.D., Whittington C.M., Belov K., Maghzal G.J., Jermiin L.S., Hunt N.H. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2009, 153:137-144.
45. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 2004, 25(3):469-479. (Mar).